CTD Holdings starts enrolment in Phase I/II trial of Trappsol Cyclo for NPC

US-based biotechnology firm CTD Holdings has started patient enrolment in the Phase I/II clinical trial of Trappsol Cyclo to treat patients suffering from Niemann-Pick disease type C (NPC) in Europe.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news